CLSI M100 S23 : 23ED 2013

Abstract
Committee Membership
Summary of Major Changes in This Document
Summary of CLSI Processes for Establishing Interpretive
Criteria and Quality Control Ranges
Summary of CLSI Reference Methods vs Commercial
Methods and CLSI vs FDA Interpretive Criteria
(Breakpoints)
Subcommittee on Antimicrobial Susceptibility Testing
Mission Statement
Instructions for Use of Tables
Appendix A - Suggestions for Confirmation of
             Resistant (R), Intermediate (I), or
             Nonsusceptible (NS) Antimicrobial
             Susceptibility Test Results and
             Organism Identification
Appendix B - Intrinsic Resistance
Appendix C - Quality Control Strains for Antimicrobial
             Susceptibility Tests
Appendix D - Cumulative Antimicrobial Susceptibility
             Report for Bacteroides fragilis Group Organisms
Appendix E - Cumulative Antimicrobial Susceptibility
             Report for Anaerobic Organisms Other than
             Bacteroides fragilis Group
Glossary I (Part 1) - Beta-Lactams: Class and Subclass
                      Designation and Generic Name
Glossary I (Part 2) - Non-Beta-Lactams: Class and
                      Subclass Designation and Generic Name
Glossary II - Abbreviations/Routes of Administration/Drug
              Class for Antimicrobial Agents Listed in M100-S23
Glossary III - List of Identical Abbreviations Used for
               More Than One Antimicrobial Agent in US
               Diagnostic Products
Informational - User Questions and Subcommittee Responses
The Quality Management System Approach
Related CLSI Reference Materials